Kornimate/medical-research-clean huggingface dataset:
hdl lipidomic, proteomic and functional changes in women after eating eggs

Conditions: Overweight; Obesity

Summary: the objective of this randomized, single blinded cross-over study is to investigate effects of daily egg versus yolk-free egg substitute consumption on high density lipoprotein (hdl) composition and function in a population of overweight and obese postmenopausal women.

the investigators hypothesize that after 4 weeks of daily consumption of whole egg versus yolk-free egg will result in differences in the hdl composition and profile of lipids and proteins (lipidome and proteome), which will be associated with changes in hdl functionality. it is further hypothesized that it will be possible to discriminate between responders and non-responders to eggs in terms of increasing both apolipoprotein a-1 (apoa-i) content in the plasma, corresponding with more protective hdl particles; and increasing hdl functionality (cholesterol efflux and anti-oxidant capacity). subjects will consume an egg free diet during study protocols, except for the egg meal provided by the study. the study is comprised of two 4-week feeding periods with a 4-week washout between testing periods. while on the study, subjects will consume the equivalent of two eggs for breakfast, either whole egg or yolk-free egg. following a 2-week low-egg lead-in period, subjects will be randomly selected to start on either arm and cross over to the other arm after the 4-week washout period. measured results will be compared between the baseline and the 4-week end point for each arm. additional comparisons may be made between 4-week endpoints.

Eligibility criteria:
inclusion criteria: * female * 45-70 years old * overweight or obese (bmi 25-35 kg/m2) * post-menopausal (confirmed by clinical hormone levels assessed at screening if within one year of last menses) * plasma hdl cholesterol greater than or equal to 50 mg/dl. exclusion criteria: * documented chronic diseases including diabetes, thyroid disease, metabolic syndrome, cancer (active), or previous cardiovascular events * having 3 or more traits of metabolic syndrome * egg allergy or multiple food allergies or food intolerances that would significantly limit food intake * smoker * current consumption more than 1 alcoholic drink/ day * extreme dietary or exercise patterns * recent weight fluctuations (greater than 10% in the last six months) * anemia * taking prescription lipid medications or other supplements known to alter lipoprotein metabolism such as isoflavones, red yeast rice, or \> 1 g of fish oil/day. * taking exogenous hormones (i.e. hormone replacement therapy)
bariatric surgery and pharmacokinetics of gabapentin

Conditions: Obesity, Morbid

Summary: changes to gastric ph, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. these factors are potentially influenced by bariatric surgery. little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. in this study the pharmacokinetic effects of bariatric surgery on gabapentin are investigated.


Eligibility criteria:
inclusion criteria: * preparing to undergo gastric bypass or sleeve gastrectomy in central norway * being a norwegian citizen exclusion criteria: * having previously undergone resections in the gi-tract

Keywords: bariatric surgery gastrointestinal tract biological availability pharmacokinetics gabapentin
evaluation of conjunctival autografting with mmc application versus ologen implantation of recurrent pterygium

Conditions: Recurrent Pterygium of Eye

Summary: ologen implantation with conjunctival autografting shows promising results in surgical management of recurrent pterygium comparable to mmc application with conjunctival autografting with mild non vision threatening postoperative complications.

patients were randomly enrolled into two groups. group a included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of mitomycin c (0.2 mg/ml). group b included 31 eyes of 31 who underwent conjunctival autografting augmented with ologen implantation. all patients had a recurrent nasal pterygium after one surgical session for removal of the primary one. any patient with primary nasal pterygium, or patients with recurrent pterygium who had more than one session for surgical removal were excluded. as well, patients with cicatrizing conjunctival disease or previous conjunctival surgery were excluded from the study. a comprehensive ophthalmic examination, including best-corrected visual acuity testing, slit-lamp examination, goldmann applanation tonometry, fundus examination, and examination of ocular motility, was carried out for all patients. according to their corneal extent, pterygia were classified into 3 grades: grade 1: fibrovascular proliferations extend up to one quarter of the corneal diameter. grade 2: fibrovascular proliferations extend up to the center of the cornea. grade 3: fibrovascular proliferations extend beyond the visual axis. consents were taken from all patients and research was approved by the institutional review board. all measures were in accordance with the tenets of the declaration of helsinki. as for group a, 0.2 mg/ml mmc was prepared by reconstituting 2 mg vial of mitomycin with 10 ml sterile water for injection. when using mitomycin 10 mg vial, the same concentration was achieved by reconstituting the 10 mg vial 10 ml sterile water for injection. then 1 ml of the prepared solution was diluted with 4 ml of saline to achieve 0.2 mg/ml (0.02% solution). this solution is stable for 2 weeks under refrigeration, and 24 hours at room temperature (59° to 86°f). as for group b, 1×2 or 2×2 square millimeter porous collagen matrix was used for each patient

Eligibility criteria:
inclusion criteria: recurrent nasal pterygium after one surgical session for removal of the primary one exclusion criteria: * primary nasal pterygium, * recurrent pterygium with more than one session for surgical removal
the value of novel thrombus markers in the diagnosis and treatment of acute pulmonary embolism

Conditions: Acute Pulmonary Embolism

Summary: in response to the high mortality rate of patients with acute pulmonary embolism (ape) and the fact that only a small proportion of deceased patients can receive correct diagnosis, this study will use a sensitive, non-invasive, and feasible new thrombus molecular marker (tat/pic/tm/t-paic) to detect and evaluate the activation of the coagulation and fibrinolysis systems and endothelial system damage in patients, in order to monitor the early diagnosis and treatment of ape, reduce mortality, and improve patient quality of life. therefore, this study intends to include 200 newly diagnosed ape patients to evaluate the sensitivity and specificity of the single and combined application of novel thrombus molecular markers for ape diagnosis; detect the biomarker results of patients at different time points before and after treatment, and evaluate their value in ape treatment monitoring; track and follow up on patients after discharge to explore the prognostic value of biomarkers for ape.


Eligibility criteria:
inclusion criteria: * 1.patients diagnosed with ape for the first time through ctpa in clinical practice and who have not received anticoagulant therapy in the past month; 2.age ≥ 18 years old. exclusion criteria: * 1. complicated with other thrombotic diseases, complicated with important organ damage such as heart, liver, kidney, and previous history of pulmonary embolism; 2. malignant tumors; 3. renal dialysis patients; 4. antiphospholipid syndrome; 5. immune system diseases; 6. hematological diseases; 7. dic caused by severe infection; 8. patients judged by clinicians to be unfit for clinical practice.
efficiency of repetitive transcranial magnetic stimulation (rtms) sessions after a successful 3 week-treatment in fibromyalgia

Conditions: Fibromyalgia

Summary: maintenance rtms sessions after a successful 3week-rtms treatment for subjects with fibromyalgia may maintain the clinical improvement.

in a previous pilot study, a 3 week treatment with rtms in fibromyalgia subjects induced a 40% improvement of pain feeling. three months later, the pain level was still significantly reduced in comparison with the beginning of the treatment, but the clinical improvement was less than at the end of the treatment. we thus propose to realize real or sham rtms sessions at 3 weeks interval during 6 months with subjects presenting a significant clinical improvement after a 3 week-rtms or sham treatment to evaluate the response maintenance.

Eligibility criteria:
inclusion criteria: * presence of the criteria from the american college of rheumatology (2010)for fibromyalgia diagnosis, * painful state for more than six months, * visual analogic scale evaluation \> or = 5, * age between 18 and 70, * no modification in therapeutic treatment one month before and during the protocol * presence of actual or prior antalgic chronic treatment : pregabalin, duloxetine, milnacipran, gabapentin, venlafaxine, laroxyl, grade 1 or 2 antalgic * residence in limoges or the periphery, or the ability to come to the hospital for the treatment exclusion criteria: * presence of non stabilized psychiatric comorbidity (personality trouble, addiction, suicide attempt, non controlled affective trouble), * active epilepsy, * previous cerebral traumatism, or cerebral surgery, intra-cranial hyper tension, * pacemaker, metallic pieces in the brain, cochlear ocular implant, or any metallic material contra indicating magnetic resonance imaging. * clozapine, bupropion, methadon, theophyllin, or other non chemical antalgic technic established during the previous month(kinesitherapy, relaxation, hypnosis...), * pregnancy, or administrative and judiciary protection, absence of health insurance.

Keywords: rtms fibromyalgia sham maintenance session pain
trial to evaluate a specified type of apgar

Conditions: Postnatal Condition of a Newborn Infant

Summary: it is of importance to predict the risk to develop problems after birth. virginia apgar developed a score more than 50 years ago that allows a description of the condition of newborns at 1, 5 and 10 minutes after birth. the apgar score is used for every newborn, however, its applicability is restricted in preterm infants and resuscitated newborns. thus, two scores have been suggested recently - the specified apgar and the expanded-apgar score. by combining both scores the combined-apgar has been developed as a new delivery room tool. the purpose of this study is to determine whether the combined-apgar predicts poor outcome better than the specified- or expanded apgar alone.

since the conventional apgar score has its limitations in preterm or resuscitated infants, specifications of the individual items of the original apgar score were suggested (specified apgar). the specified-apgar will slightly change the apgars' perspective, but will not alter the number of its components. the advantage of the proposed definitions is the applicability in all infants, regardless of resuscitative efforts or gestational age. however, neither the conventional nor the specified-apgar score describes the condition of the infant. that problem has been taken up by the american academy of pediatrics (aap)and the american college of obstetricians and gynecologists (acog). they suggested to use an expanded apgar score reporting form (expanded-apgar)that accounts for concurrent resuscitative interventions. whereas the specified-apgar score describes the condition of the infant, the expanded-apgar is a measure of interventions needed to achieve this condition. by combining both scores (combined-apgar) the postnatal condition is described in more detail than by a single score alone. to validate the accuracy of these scores in a population of very preterm infants, the present prospective, observational, international multicenter study is planned. until today there is no gold standard available to describe infant's conditions and interventions. for the evaluation of the scores it was therefore hypothesized that the combined apgar predicts poor outcome (defined as either death or any major morbidity) better than the specified apgar or expanded apgar alone. prediction of poor outcome was used as a surrogate parameter to test the predictive value of the combined-apgar score in a clinical setting for preterm infants. in an attempt to determine how strong of an association there is between the combined apgar score and neurologic impairment in early childhood, we are presently engaged in a long-term follow-up of all surviving infants at a corrected age of 24 months.

Eligibility criteria:
inclusion criteria: * gestational age below 32 weeks * born within the study centres exclusion criteria: * missing informed consent * outborn * major congenital abnormalities * death in the delivery room

Keywords: apgar score neonatal assessment preterm infants resuscitation
rivastigmine capsules in patients with probable vascular dementia

Conditions: Vascular Dementia

Summary: the goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.


Eligibility criteria:
inclusion criteria: * patients who complete the double-blind treatment phase or those who have dropped out early in the study, but have returned for all the remaining scheduled efficacy assessments (retrieved drop-out patients) without significant protocol violations are eligible to participate. exclusion criteria: * retrieved drop-out patients, who have been treated with other cholinergic drugs during the past 4 weeks

Keywords: dementia vascular rivastigmine stroke memory loss
postnatal choline supplementation in children with prenatal alcohol exposure

Conditions: Fetal Alcohol Spectrum Disorders; Fetal Alcohol Syndrome; Partial Fetal Alcohol Syndrome; Alcohol Related Neurodevelopmental Disorder; Prenatal Alcohol Exposure

Summary: the purpose of this study is to determine if choline bitartrate can be administered daily to children with prenatal alcohol exposure, ages 2.5 to 5, as a potential treatment for brain development and cognitive functioning.


Eligibility criteria:
inclusion criteria: * available parent or legal guardian capable of participating in informed consent process * documented history of heavy prenatal alcohol exposure (self-report, social service records, or adoption records) or presence of facial dysmorphology characteristic of fasd or both * evidence of cognitive deficit in at least one neurocognitive domain exclusion criteria: * history of neurological condition (ex. epilepsy, cerebral palsy, traumatic brain injury) * history of medical condition known to affect brain function * history of other neurodevelopmental disorder (ex. autism, down syndrome) * history of very low birthweight (\<1500 grams) * history of prenatal exposure to drugs other than alcohol, nicotine, and caffeine

Keywords: fasd fas alcohol prenatal alcohol
research on anxiety and depression: computer-assisted therapy

Conditions: Mood Disorders; Anxiety Disorders

Summary: this study examines how online self-guided programs can improve mood and anxiety symptoms. these programs use exercises from cognitive-behavioral therapy, which is an evidence-based treatment for depression and anxiety. the purpose of this study is to learn who will do best with the online format. our aim is to learn for whom online self-guided interventions are most efficacious. this knowledge is important because it will help inform clinicians and patients about who might benefit from this type of intervention versus who would need the assistance of a therapist. more specifically, we hope to figure out who would benefit from solely an online intervention and who would benefit from an online intervention in addition to other treatment.


Eligibility criteria:
inclusion criteria: * previous participation in the rad study in our laboratory rad study inclusion criteria are: * 18+ years of age * fluent and literate in english * can provide informed consent * fmri scanning eligibility, including no evidence of any form of metal embedded in the body (e.g., metal wires, nuts, bolts, screws, plates, sutures) exclusion criteria: * anyone who has not already completed the rad study will be excluded. rad study exclusion criteria are: * presence of suicidal ideations representing imminent risk * general medical condition, disease, or neurological disorder that interferes with the assessments * mild traumatic brain injury (history of physical brain injury or blow to the head resulting in loss of consciousness greater than five minutes) and which could interfere with doing the assessments * severe impediment to vision, hearing and/or hand movement, likely to interfere with ability to complete the assessments * unable and/or unlikely to follow the study protocols * pregnant or breastfeeding
efficacy of pantoprazole 20/40 mg once daily (od) in patients older than 12 years who have gastrointestinal symptoms of reflux disease

Conditions: Gastroesophageal Reflux Disease

Summary: the aim of this study was to evaluate the effect of 14 days treatment with pantoprazole 40 mg and 20 mg on gastroesophageal reflux disease (gerd) related symptoms in a large patient population.


Eligibility criteria:
main inclusion criteria: * outpatients with gastroesophageal reflux disease (gerd) main exclusion criteria: * criteria as defined in the summary of product characteristics

Keywords: ppi therapy pantoprazole gerd (erosive gastroesophageal reflux disease)
study of vorinostat plus capecitabine (x) and cisplatin (p) for 1st line treatment of metastatic or recurrent gastric cancer: zolinza+xp

Conditions: Gastric Cancer; Histone Deacetylase Inhibitor

Summary: there is scientific rationale for exploring the role of vorinostat, histone deacetylase inhibitor with capecitabine (x) and cisplatin (p), one of standard chemotherapy in patients with advanced gastric cancer. xp is a new standard of care in advanced gastric cancer (agc) and vorinostat is a novel targeted agent that prevents tumor cell proliferation, survival and angiogenesis through histone deacetylase inhibition.


Eligibility criteria:
inclusion criteria: * histologically confirmed unresectable or metastatic advanced gastric adenocarcinoma * completion of adjuvant chemotherapy 6 months before the study, or no previous chemotherapy * age 18 to 70 years old * eastern cooperative oncology group (ecog) performance status 2 or less * estimated life expectancy of more than 3 months * presence of measurable or evaluable disease * adequate bone marrow function (anc \>1,500/µl and platelets\>100,000/µl), * adequate renal function: creatinine \< 1 x upper normal limit (unl) or creatinine clearance 60ml/min or less * adequate hepatic function: bilirubin \< 1.5 x unl, aspartate aminotransferase (ast)/alanine aminotransferase (alt) levels \< 2.5 x unl (\< 5 x upper limit of normal for patients with liver involvement of their cancer), alkaline phosphatase \< 5 x unl (except in case of bone metastasis without any liver disease) * written informed consent exclusion criteria: * prior exposure to any histone deacetylase (hdac) inhibitor (however, valproic acid would be allowed if a 30-day wash-off period is provided.) * previous adjuvant treatment with capecitabine or platinums * contraindication to any drug contained in the chemotherapy regimen * other tumor type than adenocarcinoma * presence or history of central nervous system (cns) metastasis * gastric outlet or bowel obstruction * evidence of serious gastrointestinal bleeding * peripheral neuropathy \> grade 2 * history of significant neurologic or psychiatric disorders * history of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix * pregnant or lactating women, women of childbearing potential not employing adequate contraception * active human immunodeficiency virus (hiv) infection * viral hepatitis infections * other serious illness or medical conditions

Keywords: gastric cancer histone deacetylase inhibitor 1st line chemotherapy
a rct of centeringpregnancy on birth outcomes

Conditions: Pregnancy; Preterm Birth

Summary: the purpose of this study is to evaluate whether centeringpregnancy group prenatal care can improve preterm birth rate and other birth outcomes, maternal psychosocial and behavioral outcomes, and decrease the racial difference in selected birth outcomes among african american and white women, compared to individual prenatal care.

this is a randomized controlled trial to compare biomedical, behavioral and psychosocial outcomes by race among pregnant women who participate in centeringpregnancy group prenatal care, to women in the traditional individual prenatal care and to investigate whether improving women's stress, activation and engagement will explain the potential benefits of centeringpregnancy on outcomes and health disparities. the trial will be conducted in a large prenatal care center in south carolina. eligible white and black women will be recruited before 20 weeks of gestational age with low risk pregnancy.

Eligibility criteria:
inclusion criteria: 1. pregnant women aged between 14-45 years 2. entry prenatal care before 20 6/7 weeks gestational age (defined as attendance at the intake screening visit). patients must be randomized by 23 6/7 weeks gestational age. exclusion criteria: 1. medical complications of pregnancy that would preclude prenatal care provision by nurse practitioners or participation in group care * pregestational diabetes, * severe chronic hypertension requiring medication, * morbid obesity with bmi \>49.99 * renal disease with baseline proteinuria \>1g/24 hours * any disease requiring chronic immunosuppression (sle, solid organ transplant) * active pulmonary tuberculosis * sickle cell anemia * human immunodeficiency virus infection * other medical conditions that would exclude women from group care at the discretion of the pi 2. pregnancy complications that would preclude prenatal care provision by nurse practitioners or participation in group care * multiple gestation * lethal fetal anomalies * other pregnancy complications that would exclude women from group care at the discretion of the pi 3. social and behavioral complications of pregnancy which would preclude prenatal care provision by nurse practitioners or participation in group care * current incarceration * severe psychiatric illness

Keywords: racial disparities